Notes d’épisode
It's a quiet week for acromegaly-specific trial data — the research side leans mechanistic and clinical-management, headlined by a novel long-acting GH receptor antagonist — while rare disease industry news brought a fresh Phase 2 win for Silence Therapeutics, an $800M Stargardt disease acquisition, a CRISPR safety insight from Intellia, and a Washington fight over whether orphan drugs get carved out of Medicare price pilots.

